Have a personal or library account? Click to login
Efficacy of oral versus intravenous steroids in the treatment of pediatric immune thrombocytopenic purpura: A single center experience Cover

Efficacy of oral versus intravenous steroids in the treatment of pediatric immune thrombocytopenic purpura: A single center experience

Open Access
|Jun 2025

References

  1. Despotovic JM, Grimes AB. Pediatric ITP: is it different from adult ITP?. Hematology 2014, the American Society of Hematology Education Program Book .2018; (1):405-11.
  2. Laghmouchi A, Graça NAG, Voorberg J. Emerging Concepts in Immune Thrombotic Thrombocytopenic Purpura. Front Immunol. 2021; 12:757192.
  3. Grace RF, Lambert MP. An update on pediatric ITP: differentiating primary ITP, IPD, and PID. Blood 2022; 140(6):542-55.
  4. Kochhar M, Neunert C. Immune thrombocytopenia: A review of upfront treatment strategies. Blood Rev 2021; 49:100822.
  5. Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Advces.2019;3(22) :3780-817.
  6. Provan D, Semple JW. Recent advances in the mechanisms and treatment of immune thrombocytopenia. EBioMedicine. 2022;76.
  7. Akram NN, Ibrahim BA, Ali SM, Nori W. Clinical and laboratory characteristics of children with neurological presentations of COVID-19: a single-center experience. J Med Life. 2022; 15:1294–8.
  8. Choi PYI, Merriman E, Bennett A, et al. Consensus guidelines for the management of adult immune thrombocytopenia in Australia and New Zealand. Medical Journal of Australia.2022; 216(1):43-52.
  9. Cuker A, Prak ETL, Cines DB. Can immune thrombocytopenia be cured with medical therapy? Semin Thromb Hemost. 2015;41(4) :395-404.
  10. Akram NN, Abed MY. Indications and Outcome of Albumin Infusion in a Neonatal Population: A Cross-Sectional Study. Journal of Medicinal and Chemical Sciences 2022;5(1): 129-136
  11. Mithoowani S, Gregory-Miller K, Goy J, et al. High-dose dexamethasone compared with prednisone for previously untreated primary immune thrombocytopenia: a systematic review and meta-analysis. Lancet Haematol .2016; 3(10):e489-96.
  12. Mjali A, Matti BF, Abbas NT, et al. Do we need local guidelines for the diagnosis and management of immune thrombocytopenia in Iraq? Journal of Applied Hematology 2023;14(2):146-56.
  13. Ghani S, Baaker R, Akram N. Significance of extreme leukocytosis in evaluation of febrile children aged 3-36 months: A single center experience. Iraqi Journal of Hematology 2016;5(2):167-72.
  14. I Alezzi J, S. AlKhateeb M, Wisam Hassan E. The Outcome of Withholding Pharmacologic Treatment in Children with Acute ITP. Diyala Journal of Medicine. 2019; 17:85–92.
  15. Jesudas R, Takemoto CM. Where have all the platelets gone? HIT, DIC, or something else? Hematology. 2023(1):43-50.
  16. Allegra A, Cicero N, Mirabile G, Giorgianni CM, Gangemi S. Novel Biomarkers for Diagnosis and Monitoring of Immune Thrombocytopenia. Int J Mol Sci. 2023;24 (5):4438.
  17. Buchanan GR, Adix L. Grading of hemorrhage in children with idiopathic thrombocytopenic purpura. Journal of Pediatrics. 2002;141 (5):683-8.
  18. Wei Y, Ji X Bin, Wang YW, et al. High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: A prospective multicenter randomized trial. Blood 2016;127(3):296-302.
  19. Andersen JC. Response of resistant idiopathic thrombocytopenic purpura to pulsed high-dose dexamethasone therapy. New England Journal of Medicine. 1994; 330(22):1560-4.
  20. Cydulka RK. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. Ann Emerg Med . 2004;43(5):676-7.
  21. Cheng Y, Wong RS, Soo YO, et al. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. New England Journal of Medicine. 2003; 349(9):831-6.
  22. Jaime-Pérez JC, Aguilar-Calderón P, Jiménez-Castillo RA, Ramos-Dávila EM, Salazar-Cavazos L, Gómez-Almaguer D. Treatment outcomes and chronicity predictors for primary immune thrombocytopenia: 10-year data from an academic center. Ann Hematol. 2020; 99:2513-20.
  23. Alakkas Z, Alzaedi OA, Somannavar SS, et al. Steroid-induced diabetes ketoacidosis in an immune thrombocytopenia patient: A case report and literature review. American Journal of Case Reports 2020;21:e923372-1.
  24. Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829-66.
  25. Fish JD, Lipton JM, Lanzkowsky P. Lanzkowsky’s Manual of Pediatric Hematology and Oncology. eBook. Academic Press, 2021:1401.
  26. Mazzucconi MG, Fazi P, Bernasconi S, et al. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood. 2007;109(4):1401-7.
  27. Akram NN, Jaafar MM, Abdulqader SK, et al. Clinical Characteristics and Therapeutic Management of Osteogenesis Imperfecta in Iraqi Children. Al-Rafidain Journal of Medical Sciences (ISSN 2789-3219 ) 2023;5:S189-194.
DOI: https://doi.org/10.2478/amma-2025-0025 | Journal eISSN: 2668-7763 | Journal ISSN: 2668-7755
Language: English
Page range: 116 - 120
Submitted on: Mar 11, 2025
Accepted on: May 30, 2025
Published on: Jun 30, 2025
Published by: University of Medicine, Pharmacy, Science and Technology of Targu Mures
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2025 Essam Ahmed Abdullah, Nabeeha Najatee Akram, published by University of Medicine, Pharmacy, Science and Technology of Targu Mures
This work is licensed under the Creative Commons Attribution 4.0 License.